Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1
- Authors:
- Su-Yeon Lee
- Jinie Kwon
- Kyung-Ah Lee
-
Affiliations: Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Gyeonggi 13488, Republic of Korea - Published online on: March 1, 2021 https://doi.org/10.3892/or.2021.7998
- Article Number: 47
-
Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI | |
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
Markowska A, Sajdak S, Markowska J and Huczynski A: Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer. Eur J Med Chem. 142:87–94. 2017. View Article : Google Scholar : PubMed/NCBI | |
Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M and Pavlidis N: Poly (ADP-Ribose) polymerase inhibitors: Talazoparib in ovarian cancer and beyond. Drugs R D. 20:55–73. 2020. View Article : Google Scholar : PubMed/NCBI | |
Levine B, Sinha SC and Kroemer G: Bcl-2 family members: Dual regulators of apoptosis and autophagy. Autophagy. 4:600–606. 2008. View Article : Google Scholar | |
Inohara N, Gourley TS, Carrio R, Muñiz M, Merino J, Garcia I, Koseki T, Hu Y, Chen S and Núñez G: Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death. J Biol Chem. 273:32479–32486. 1998. View Article : Google Scholar : PubMed/NCBI | |
Kang Y, Lee DC, Han J, Yoon S, Won M, Yeom JH, Seong MJ, Ko JJ, Lee KA, Lee K and Bae J: NM23-H2 involves in negative regulation of Diva and Bcl2L10 in apoptosis signaling. Biochem Biophys Res Commun. 359:76–82. 2007. View Article : Google Scholar : PubMed/NCBI | |
Naumann U, Weit S, Wischhusen J and Weller M: Diva/Boo is a negative regulator of cell death in human glioma cells. FEBS Lett. 505:23–26. 2001. View Article : Google Scholar : PubMed/NCBI | |
Zhang H, Holzgreve W and De Geyter C: Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway. Hum Mol Genet. 10:2329–2339. 2001. View Article : Google Scholar : PubMed/NCBI | |
Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, et al: BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget. 3:490–501. 2012. View Article : Google Scholar : PubMed/NCBI | |
Nougarede A, Popgeorgiev N, Kassem L, Omarjee S, Borel S, Mikaelian I, Lopez J, Gadet R, Marcillat O, Treilleux I, et al: Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10. Cancer Res. 78:1404–1417. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bai Y, Wang J, Han J, Xie XL, Ji CG, Yin J, Chen L, Wang CK, Jiang XY, Qi W and Jiang HQ: BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo. Mol Carcinog. 56:1137–1149. 2017. View Article : Google Scholar : PubMed/NCBI | |
Xu JD, Furuya T, Cao XX, Liu XL, Li QQ, Wang WJ, Xu JW, Xu ZD, Sasaki K and Liu XP: Loss of BCL2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma. Histopathology. 57:814–824. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lee SY, Kim EY, Kim KH and Lee KA: Bcl2l10, a new Tpx2 binding partner, is a master regulator of Aurora kinase A in mouse oocytes. Cell Cycle. 15:3296–3305. 2016. View Article : Google Scholar : PubMed/NCBI | |
Damodaran AP, Vaufrey L, Gavard O and Prigent C: Aurora a kinase is a priority pharmaceutical target for the treatment of cancers. Trends Pharmacol Sci. 38:687–700. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yan M, Wang C, He B, Yang M, Tong M, Long Z, Liu B, Peng F, Xu L, Zhang Y, et al: Aurora-a kinase: A potent oncogene and target for cancer therapy. Med Res Rev. 36:1036–1079. 2016. View Article : Google Scholar : PubMed/NCBI | |
Lee SY, Kwon J, Woo JH, Kim KH and Lee KA: Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells. Int J Oncol. 56:618–629. 2020.PubMed/NCBI | |
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
Trapnell C, Pachter L and Salzberg SL: TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics. 25:1105–1111. 2009. View Article : Google Scholar : PubMed/NCBI | |
Quinlan AR and Hall IM: BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics. 26:841–842. 2010. View Article : Google Scholar : PubMed/NCBI | |
Roberts A, Trapnell C, Donaghey J, Rinn JL and Pachter L: Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol. 12:R222011. View Article : Google Scholar : PubMed/NCBI | |
Laurenti G and Tennant DA: Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): Three players for one phenotype in cancer? Biochem Soc Trans. 44:1111–1116. 2016. View Article : Google Scholar : PubMed/NCBI | |
Bailey MJ, Shield-Artin KL, Oliva K, Ayhan M, Reisman S and Rice GE: Stage-specific analysis of plasma protein profiles in ovarian cancer: Difference in-gel electrophoresis analysis of pooled clinical samples. J Carcinog. 12:102013. View Article : Google Scholar : PubMed/NCBI | |
Mikata R, Fukai K, Imazeki F, Arai M, Fujiwara K, Yonemitsu Y, Zhang K, Nabeya Y, Ochiai T and Yokosuka O: BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer. Oncol Rep. 23:1701–1708. 2010.PubMed/NCBI | |
Xu JD, Cao XX, Long ZW, Liu XP, Furuya T, Xu JW, Liu XL, De Xu Z, Sasaki K and Li QQ: BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells. J Pathol. 223:400–409. 2011. View Article : Google Scholar : PubMed/NCBI | |
Jen J and Wang YC: Zinc finger proteins in cancer progression. J Biomed Sci. 23:532016. View Article : Google Scholar : PubMed/NCBI | |
Cheng Y, Liang P, Geng H, Wang Z, Li L, Cheng SH, Ying J, Su X, Ng KM, Ng MH, et al: A novel 19q13 nucleolar zinc finger protein suppresses tumor cell growth through inhibiting ribosome biogenesis and inducing apoptosis but is frequently silenced in multiple carcinomas. Mol Cancer Res. 10:925–936. 2012. View Article : Google Scholar : PubMed/NCBI | |
Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA and Moses MA: Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Res. 67:8736–8741. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB and Lin SY: ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res. 71:6524–6534. 2011. View Article : Google Scholar : PubMed/NCBI | |
Jen J, Lin LL, Chen HT, Liao SY, Lo FY, Tang YA, Su WC, Salgia R, Hsu CL, Huang HC, et al: Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. 35:2357–2369. 2016. View Article : Google Scholar : PubMed/NCBI | |
Serra RW, Fang M, Park SM, Hutchinson L and Green MR: A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife. 3:e023132014. View Article : Google Scholar : PubMed/NCBI | |
Yang L, Zhang L, Wu Q and Boyd DD: Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets. J Biol Chem. 283:35295–35304. 2008. View Article : Google Scholar : PubMed/NCBI | |
Bang HS, Choi MH, Kim CS and Choi SJ: Gene expression profiling in undifferentiated thyroid carcinoma induced by high-dose radiation. J Radiat Res. 57:238–249. 2016. View Article : Google Scholar : PubMed/NCBI | |
Omura N, Li CP, Li A, Hong SM, Walter K, Jimeno A, Hidalgo M and Goggins M: Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther. 7:1146–1156. 2008. View Article : Google Scholar : PubMed/NCBI | |
Durinck S, Stawiski EW, Pavia-Jimenez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, et al: Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 47:13–21. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liu H, Li F, Zhu Y, Li T, Huang H, Lin T, Hu Y, Qi X, Yu J and Li G: Whole-exome sequencing to identify somatic mutations in peritoneal metastatic gastric adenocarcinoma: A preliminary study. Oncotarget. 7:43894–43906. 2016. View Article : Google Scholar : PubMed/NCBI | |
Schnabl B, Hu K, Muhlbauer M, Hellerbrand C, Stefanovic B, Brenner DA and Schölmerich J: Zinc finger protein 267 is up-regulated during the activation process of human hepatic stellate cells and functions as a negative transcriptional regulator of MMP-10. Biochem Biophys Res Commun. 335:87–96. 2005. View Article : Google Scholar : PubMed/NCBI | |
Schnabl B, Valletta D, Kirovski G and Hellerbrand C: Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. Exp Mol Pathol. 91:695–701. 2011. View Article : Google Scholar : PubMed/NCBI | |
Baras A and Moskaluk CA: Intracellular localization of GASP/ECOP/VOPP1. J Mol Histol. 41:153–164. 2010. View Article : Google Scholar : PubMed/NCBI | |
Baras A, Yu Y, Filtz M, Kim B and Moskaluk CA: Combined genomic and gene expression microarray profiling identifies ECOP as an upregulated gene in squamous cell carcinomas independent of DNA amplification. Oncogene. 28:2919–2924. 2009. View Article : Google Scholar : PubMed/NCBI | |
Gao C, Pang M, Zhou Z, Long S, Dong D, Yang J, Cao M, Zhang C, Han S and Li L: Epidermal growth factor receptor-coamplified and overexpressed protein (VOPP1) is a putative oncogene in gastric cancer. Clin Exp Med. 15:469–475. 2015. View Article : Google Scholar : PubMed/NCBI | |
Baras AS, Solomon A, Davidson R and Moskaluk CA: Loss of VOPP1 overexpression in squamous carcinoma cells induces apoptosis through oxidative cellular injury. Lab Invest. 91:1170–1180. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P and Zhang Y: Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell. 8:1207–1217. 2001. View Article : Google Scholar : PubMed/NCBI | |
Akiyama Y, Koda Y, Byeon SJ, Shimada S, Nishikawaji T, Sakamoto A, Chen Y, Kojima K, Kawano T, Eishi Y, et al: Reduced expression of SET7/9, a histone mono-methyltransferase, is associated with gastric cancer progression. Oncotarget. 7:3966–3983. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Yang S, Hu J, Yu C, He M and Cai Z: Increased expression of SETD7 promotes cell proliferation by regulating cell cycle and indicates poor prognosis in hepatocellular carcinoma. PLoS One. 11:e01549392016. View Article : Google Scholar : PubMed/NCBI | |
Manstein DJ and Mulvihill DP: Tropomyosin-mediated regulation of cytoplasmic myosins. Traffic. 17:872–877. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gunning PW, Hardeman EC, Lappalainen P and Mulvihill DP: Tropomyosin-master regulator of actin filament function in the cytoskeleton. J Cell Sci. 128:2965–2974. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kabbage M, Trimeche M, Ben Nasr H, Hammann P, Kuhn L, Hamrita B and Chahed K: Tropomyosin-4 correlates with higher SBR grades and tubular differentiation in infiltrating ductal breast carcinomas: An immunohistochemical and proteomics-based study. Tumour Biol. 34:3593–3602. 2013. View Article : Google Scholar : PubMed/NCBI | |
Tang HY, Beer LA, Tanyi JL, Zhang R, Liu Q and Speicher DW: Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. J Proteomics. 89:165–178. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhao X, Jiang M and Wang Z: TPM4 promotes cell migration by modulating F-actin formation in lung cancer. Onco Targets Ther. 12:4055–4063. 2019. View Article : Google Scholar : PubMed/NCBI | |
Lomnytska MI, Becker S, Bodin I, Olsson A, Hellman K, Hellström AC, Mints M, Hellman U, Auer G and Andersson S: Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: Diagnostic and prognostic value. Br J Cancer. 104:110–119. 2011. View Article : Google Scholar : PubMed/NCBI | |
Yang R, Zheng G, Ren D, Chen C, Zeng C, Lu W and Li H: The clinical significance and biological function of tropomyosin 4 in colon cancer. Biomed Pharmacother. 101:1–7. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li DQ, Wang L, Fei F, Hou YF, Luo JM, Wei-Chen, Zeng R, Wu J, Lu JS, Di GH, et al: Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics. 6:3352–3368. 2006. View Article : Google Scholar : PubMed/NCBI | |
Yoon SJ, Kim JW, Choi KH, Lee SH and Lee KA: Identification of oocyte-specific diva-associated proteins using mass spectrometry. Korean J Fertil Steril. 33:189–198. 2006. | |
Yamaguchi H and Condeelis J: Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta. 1773:642–652. 2007. View Article : Google Scholar : PubMed/NCBI | |
Gimenez-Cassina A and Danial NN: Regulation of mitochondrial nutrient and energy metabolism by BCL-2 family proteins. Trends Endocrinol Metab. 26:165–175. 2015. View Article : Google Scholar : PubMed/NCBI | |
Gimenez-Cassina A, Martinez-Francois JR, Fisher JK, Szlyk B, Polak K, Wiwczar J, Tanner GR, Lutas A, Yellen G and Danial NN: BAD-dependent regulation of fuel metabolism and K(ATP) channel activity confers resistance to epileptic seizures. Neuron. 74:719–730. 2012. View Article : Google Scholar : PubMed/NCBI | |
Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, et al: Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 14:575–583. 2012. View Article : Google Scholar : PubMed/NCBI | |
Malia TJ and Wagner G: NMR structural investigation of the mitochondrial outer membrane protein VDAC and its interaction with antiapoptotic Bcl-xL. Biochemistry. 46:514–525. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wu W and Zhao S: Metabolic changes in cancer: Beyond the Warburg effect. Acta Biochim Biophys Sin (Shanghai). 45:18–26. 2013. View Article : Google Scholar : PubMed/NCBI | |
Huang S and Millar AH: Succinate dehydrogenase: The complex roles of a simple enzyme. Curr Opin Plant Biol. 16:344–349. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ashtekar A, Huk D, Magner A, La Perle K, Zhang X, Piruat JI, López-Barneo J, Jhiang SM and Kirschner LS: Sdhd ablation promotes thyroid tumorigenesis by inducing a stem-like phenotype. Endocr Relat Cancer. 24:579–591. 2017. View Article : Google Scholar : PubMed/NCBI | |
Mu X, Zhao T, Xu C, Shi W, Geng B, Shen J, Zhang C, Pan J, Yang J, Hu S, et al: Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation. Oncotarget. 8:13174–13185. 2017. View Article : Google Scholar : PubMed/NCBI | |
Ricketts C, Woodward ER, Killick P, Morris MR, Astuti D, Latif F and Maher ER: Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 100:1260–1262. 2008. View Article : Google Scholar : PubMed/NCBI | |
Aspuria PP, Lunt SY, Varemo L, Vergnes L, Gozo M, Beach JA, Salumbides B, Reue K, Wiedemeyer WR, Nielsen J, et al: Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab. 2:212014. View Article : Google Scholar : PubMed/NCBI | |
Zhang T, Wu X, Ke C, Yin M, Li Z, Fan L, Zhang W, Zhang H, Zhao F, Zhou X, et al: Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res. 12:505–512. 2013. View Article : Google Scholar : PubMed/NCBI | |
Reitman ZJ and Yan H: Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 102:932–941. 2010. View Article : Google Scholar : PubMed/NCBI | |
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483:479–483. 2012. View Article : Google Scholar : PubMed/NCBI | |
Raynaud S, Carbuccia N, Colin C, Adélaïde J, Mozziconacci MJ, Metellus P, Chinot O, Birnbaum D, Chaffanet M and Figarella-Branger D: Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. Oncol Lett. 1:883–884. 2010. View Article : Google Scholar : PubMed/NCBI | |
Rakheja D, Konoplev S, Medeiros LJ and Chen W: IDH mutations in acute myeloid leukemia. Hum Pathol. 43:1541–1551. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, et al: IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 30:7–11. 2009. View Article : Google Scholar : PubMed/NCBI | |
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI | |
Prasad B, Tian Y and Li X: Large-Scale analysis reveals gene signature for survival prediction in primary glioblastoma. Mol Neurobiol. 57:5235–5246. 2020. View Article : Google Scholar : PubMed/NCBI | |
Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, et al: Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation. Cell Rep. 19:1858–1873. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, et al: Glioblastoma therapy can be augmented by targeting IDH1-mediated NADPH biosynthesis. Cancer Res. 77:960–970. 2017. View Article : Google Scholar : PubMed/NCBI | |
Liu WS, Chan SH, Chang HT, Li GC, Tu YT, Tseng HH, Fu TY, Chang HY, Liou HH, Ger LP and Tsai KW: Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability. Breast Cancer Res. 20:252018. View Article : Google Scholar : PubMed/NCBI | |
Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB and Gottlieb E: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 7:77–85. 2005. View Article : Google Scholar : PubMed/NCBI | |
Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
Warburg O: On respiratory impairment in cancer cells. Science. 124:269–270. 1956.PubMed/NCBI | |
Barbosa IA, Machado NG, Skildum AJ, Scott PM and Oliveira PJ: Mitochondrial remodeling in cancer metabolism and survival: Potential for new therapies. Biochim Biophys Acta. 1826:238–254. 2012.PubMed/NCBI | |
Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A and Saavedra E: Energy metabolism in tumor cells. FEBS J. 274:1393–1418. 2007. View Article : Google Scholar : PubMed/NCBI | |
Koppenol WH, Bounds PL and Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 11:325–337. 2011. View Article : Google Scholar : PubMed/NCBI | |
Phan LM, Yeung SC and Lee MH: Cancer metabolic reprogramming: Importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 11:1–19. 2014.PubMed/NCBI | |
Schwartzenberg-Bar-Yoseph F, Armoni M and Karnieli E: The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 64:2627–2633. 2004. View Article : Google Scholar : PubMed/NCBI | |
Marbaniang C and Kma L: Dysregulation of glucose metabolism by oncogenes and tumor suppressors in cancer cells. Asian Pac J Cancer Prev. 19:2377–2390. 2018.PubMed/NCBI |